You did everything right. You cut back, you walked every morning, you tracked every bite. And the scale didn’t care. Somewhere in your late 40s, the weight that used to come off in a month started settling in like it had signed a lease, mostly around your middle.
So maybe you asked about one of the new weight-loss shots. Maybe you’re already on one. And maybe you’ve noticed it isn’t working quite the way it worked for your friend who’s 15 years younger.
Here’s why that matters. In late October, at The Menopause Society’s annual meeting in San Diego, researchers presented a study asking a question almost nobody had asked out loud: does menopause change how these medications work?
The early answer is maybe. And the reason it’s maybe tells you a lot about how women’s health research still works.
Key takeaways:
– Researchers reviewed records of nearly 2,400 women on semaglutide and nearly 1,500 on tirzepatide, all over 45 with a BMI above 27.
– With semaglutide, hormone therapy was associated with significantly greater and sustained weight loss.
– With tirzepatide, early extra weight loss with hormone therapy did not reach statistical significance by the end.
– The study is observational and needs confirmation in clinical trials.
– Researchers stress that weight loss is not a reason to start hormone therapy.
What the researchers looked at
The drugs in question are the GLP-1-based medications: semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound). You’ve seen the headlines. You’ve probably seen the commercials during the evening news.
A team at Mayo Clinic Florida looked back at the records of midlife women treated with these drugs for overweight or obesity: nearly 2,400 women on semaglutide and nearly 1,500 on tirzepatide. Everyone was over 45, with a BMI above 27. The question was simple. Did the women who were also on menopause hormone therapy do any differently?
The Menopause Society called it the first known large real-world cohort of its kind. Read that again. These drugs have been everywhere for years, and this is the first big look at how they behave in women going through the transition.
That’s not an oversight. That’s a pattern.
What they found
For semaglutide, women who were also on hormone therapy had greater weight loss, and they kept it off longer. The researchers called the difference significant.
For tirzepatide, the women on hormone therapy started out losing more, but by the end of the study the difference wasn’t big enough to count as statistically significant.
That second finding matters, so don’t skip past it. An earlier, smaller Mayo Clinic study of 120 women on tirzepatide, published in January, did find more weight loss with hormone therapy. This bigger study didn’t confirm it for tirzepatide. When two studies disagree, that’s science doing its job, not science failing. It means the answer isn’t settled yet.
The lead researcher put it plainly: the effect was stronger with semaglutide than with tirzepatide, which deserves further study.
Why would hormones matter at all?
Nobody knows for sure yet, and anyone who tells you they do is selling something.
There are a few reasonable possibilities. Estrogen plays a role in how the body handles appetite, fat storage, and blood sugar, and early lab research suggests it may interact with the same pathways these drugs work on. That part is still a theory.
There’s also a much more human explanation. Women whose hot flushes and night sweats are treated tend to sleep better. Women who sleep better have more energy, more patience, and more capacity to stick with the hard parts of any health plan. (Anyone who has tried to make good food choices on four hours of broken sleep knows exactly what we’re talking about.)
And there’s a third possibility the researchers themselves raised: women already on hormone therapy may be different in other ways. They may have better access to care, more regular checkups, or habits that help them do well on any treatment. An observational study can’t untangle that.
So the honest headline isn’t “hormones make the shot work better.” It’s “hormones might matter, and now someone is finally checking.”
The part nobody should skip
Here’s the line from the lead researcher I want every woman to hear: weight loss is not an indication for menopause hormone therapy.
In plain English: don’t start hormones to lose weight. That’s not what they’re for, and this study doesn’t change that.
Hormone therapy is a treatment for menopause symptoms like hot flushes, night sweats, and the sleep problems they cause. As we covered in our Research Alert, “Your Doctor Just Got a New Rulebook,” the American College of Obstetricians and Gynecologists now recommends it for those symptoms in women without a medical reason to avoid it. Weight is not on that list.
If you’re already on hormone therapy for your symptoms, this research may turn out to be one more reason it’s worth discussing as part of the bigger picture. That’s a conversation, not a prescription.
Why this research is a bigger deal than one study
Step back for a second.
Millions of women in midlife are being prescribed some of the most talked-about drugs in the world. And until now, nobody had looked at a large group of them to ask whether the biggest hormonal shift of their adult lives changes how those drugs work.
That’s the same story we’ve been telling since the beginning of this movement. Women’s bodies get treated like smaller men’s bodies with inconvenient extras. Drugs get studied, approved, and prescribed, and the question of what menopause does to the response gets asked years later, if at all.
This study doesn’t answer the question. It finally asks it. And it was presented at a meeting full of clinicians who will carry that question back into their exam rooms. That’s progress.
What this means for you
1. GLP-1s are tools, not moral judgments
If you’re using one, you’re not cheating. If you’re not, you’re not failing. Midlife weight change is driven by real biology, and you’re allowed to use real medicine for it, with your provider.
2. Tell your provider where you are in the transition
If you’re on (or considering) a GLP-1, make sure the person prescribing it knows whether you’re in perimenopause, menopause, or past it, and whether you’re on hormone therapy. Ask:
“Could my stage of menopause change how this medication works for me?”
It’s a fair question. The researchers are asking it too.
3. Treat your symptoms because they deserve treating
If hot flushes and night sweats are wrecking your sleep, that’s worth treating on its own. Better sleep helps almost everything, including your energy to take care of yourself. Hormonal and non-hormonal options both exist. Our free 7-Day Symptom Tracker + Doctor Visit Guide will help you show your provider what’s actually happening.
4. Don’t start or stop anything on your own
Not hormones, not your GLP-1, not a supplement someone in a comment section swears by. This is early research. Your provider knows your history; a headline doesn’t.
5. Watch this space
The researchers say these findings need to be confirmed in properly designed trials, and that work is coming. When it does, we’ll be here to tell you what it says, in plain English, with the receipts.
You were never the problem
If the scale stopped cooperating in your 40s, you probably blamed yourself. Your willpower. Your discipline. Your metabolism, like it was a character flaw.
Here’s the truth: your body was going through a major hormonal transition, and the medicine you were offered was never studied with that transition in mind. That’s not your failure. That’s a research gap with your name on it.
The good news is that the gap is finally getting attention, in rooms full of people who can close it.
You’re not broken. You’re not lazy. You’re a woman in a body that deserves to be studied as it actually is.
— Delaney
Want the full story? Read You’re Not Crazy... You’re Menopausal at notcrazymovement.com/book. And get the free 7-Day Symptom Tracker + Doctor Visit Guide at notcrazymovement.com.
Medical note: This post is educational and is not medical advice. The study described here was presented at a medical meeting and is observational; it shows an association, not cause and effect, and its findings need confirmation in clinical trials. Hormone therapy is not a weight-loss treatment. Don’t start or stop any medication, including hormone therapy or a GLP-1 medication, without talking to your provider.
-
A Mayo Clinic Florida study presented at The Menopause Society’s 2026 meeting found women over 45 on semaglutide plus hormone therapy had greater, more sustained weight loss. The tirzepatide difference wasn’t significant. It’s observational, and hormone therapy is not a weight-loss treatment.
-
Possibly. In a large Mayo Clinic Florida study presented in October 2026, women on seDoes hormone therapy help GLP-1 drugs work better? maglutide plus hormone therapy lost more weight and kept it off longer. For tirzepatide, the difference was not statistically significant. The findings need confirmation in trials.
-
No. The researchers say weight loss is not an indication for menopause hormone therapy. Hormone therapy treats symptoms such as hot flushes and night sweats. Talk to your provider about your options.
-
Ask whether your stage of menopause and any hormone therapy you’re on could affect how the medication works for you.
-
Midlife weight change reflects real biological shifts during the menopause transition, along with age, sleep, and lifestyle. It is not a willpower failure, and it’s worth discussing with your provider.
-
It isn’t known yet. Possible reasons include estrogen’s role in appetite and metabolism, better sleep when symptoms are treated, and differences between women who use hormone therapy and those who don’t.
Sources & References
1. The Menopause Society. “Hormone Therapy May Increase Weight Loss Effectiveness of GLP-1s,” press release, October 20, 2026. Study presented at The Menopause Society 2026 Annual Meeting, San Diego, October 20–24, 2026: “Menopause Hormone Therapy and Weight Loss Response to GLP-1-Based Therapies in Midlife Women: A Retrospective Cohort Study” (Mayo Clinic Florida). menopause.org
2. Mayo Clinic News Network. “New study links combination of hormone therapy and tirzepatide to greater weight loss after menopause,” January 27, 2026. Study published in The Lancet Obstetrics, Gynaecology, & Women’s Health. newsnetwork.mayoclinic.org
3. American College of Obstetricians and Gynecologists. Management of menopause-related vasomotor, sleep, and mood symptoms. Clinical Practice Guideline No. 13. Obstetrics & Gynecology. 2026;148(5):e345–e369. Published online October 15, 2026. acog.org
